Compare WEAV & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | MYGN |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.1M | 625.5M |
| IPO Year | 2021 | 1995 |
| Metric | WEAV | MYGN |
|---|---|---|
| Price | $6.32 | $7.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | $12.20 | ★ $12.58 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $229,790,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $19.19 | $0.06 |
| Revenue Next Year | $15.09 | $5.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.34 | 0.21 |
| 52 Week Low | $5.64 | $3.76 |
| 52 Week High | $17.63 | $16.83 |
| Indicator | WEAV | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 47.63 |
| Support Level | $6.24 | $6.43 |
| Resistance Level | $6.46 | $8.09 |
| Average True Range (ATR) | 0.22 | 0.42 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 78.74 | 44.14 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.